Beyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Leqembi's four-year success data validates the anti-amyloid approach to treating Alzheimer's disease. This breakthrough creates a ripple effect across the neurodegenerative treatment landscape, potentially de-risking similar therapies and attracting new investment capital to companies pursuing complementary strategies.
What You Need to Know
This group focuses on biotechnology companies at the forefront of Alzheimer's and neurodegenerative disease research. These stocks represent high-growth potential in a historically challenging but massive market, with companies developing next-generation therapies and diagnostic tools for early patient identification.
Why These Stocks
Each company was selected for its strategic alignment with the validated scientific mechanism behind Leqembi's success. These firms are developing treatments targeting amyloid or tau proteins, or creating advanced diagnostic tools necessary for the expanding Alzheimer's treatment market.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+468.50%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 468.5% over the next year.
Stocks Rated Buy by Analysts
13 of 16 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Medical Breakthrough Momentum
Leqembi's four-year success data represents a historic breakthrough in Alzheimer's treatment. This validation could accelerate development timelines and attract significant new investment to the entire neurodegenerative disease sector.
Proven Science Opens Doors
The anti-amyloid approach is now validated with long-term data, potentially de-risking similar therapies in development. Companies with complementary strategies may see accelerated paths to market approval and investor confidence.
Massive Market Opportunity
The Alzheimer's treatment market represents billions in potential revenue as the global population ages. Early movers in this validated therapeutic approach could capture significant market share in this expanding healthcare sector.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Unlock all the stocks in this group on Nemo
Sign up free to view all stocks in this group and never miss out on another investment opportunity with Nemo.
Sign up in 60 seconds
Zero commission trading
SIPC-protected up to $500,000
Backed by Exinity Group
6% AER interest on uninvested cash, paid out daily
AI investment insights
Discover More Opportunities
Beyond The Barrel: The Production Playbook
Exxon Mobil's recent earnings showed that boosting production can overcome low oil prices, highlighting a key strategy for success. This creates an investment opportunity in the companies providing the essential equipment and services that make increased oil and gas output possible.
Powering Production: The Oil Services Surge
Exxon Mobil's recent earnings beat, driven by higher production volumes in a low-price environment, highlights a key industry strategy. This creates an investment opportunity in companies that provide essential equipment and services for oil and gas exploration and production.
Riding The New Tech IPO Wave
Figma's blockbuster IPO has shattered a multi-year drought in major tech listings, signaling renewed investor appetite for high-growth software companies. This event may trigger a wave of public offerings from other venture-backed "unicorns," creating opportunities across the tech ecosystem.
Frequently Asked Questions
Everything you need to know about the product and billing.